News Archive - Page 3 of 4 - Navrogen : Navrogen

January 11, 2021

Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors

Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of...

September 29, 2020

Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers

Navrogen announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the commercialization of mesothelin-targeting agents.

September 14, 2020

Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic Effects

Navrogen announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to support its NAV-006 program involving the development of a next-generation rituximab that is...

February 4, 2020

Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates to Treat Humoral Immuno-Suppressed Cancers

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the...

January 31, 2020

Navrogen Opens R&D Operations at Cheyney University

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA....

November 20, 2019

Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting Agents

Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. Navrogen...